On November 3, 2026 T-Cypher Bio, a biotechnology company developing novel T cell receptor (TCR)-based T cell engagers that target high copy number antigens reported it will be presenting preclinical data on their two lead oncology programs, TC25 and TC11, in poster presentations at the 2026 SITC (Free SITC Whitepaper) annual meeting. The meeting is taking place November 4-8 in Phoenix Arizona. Details of the presentations are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TC25
Abstract #894
Title: Discovery and preclinical development of a half-life-extended TCR-based bispecific T cell engager targeting a novel cancer antigen presented across multiple solid tumor indications
Poster presentation Saturday, Nov. 7, 2026
Key Finding: Targeting TC25 with a high affinity bi-specific TCR-TCE drives potent, specific tumor cell killing of TC25-positive solid tumors
TC11
Abstract #891
Title: Pre-clinical development of a best-in-class bispecific T cell engager targeting a highly abundant peptide for the treatment of melanoma
Poster presentation Friday, Nov. 6, 2026
Key Finding
TC11 is a highly abundant, broadly expressed HLA bound melanoma target that is presented across diverse melanoma patient cohorts, including tumors previously exposed to checkpoint inhibitor therapy, and enables potent killing by T-Synapse-TC11, a TCR-TCE.
Commenting on the presentations, T-Cypher Bio Chief Executive Officer Sarah Leonard stated, "We are excited to share these promising datasets from our two lead programs which we believe provide a strong rationale for advancing development into the clinic. Both candidates have the potential to address significant unmet need in large patient populations, and these results continue to expand the body of evidence that our approach of focusing on targets with high peptide copy numbers will translate into robust clinical responses."
The targets were each identified by T-Cypher’s closed loop, wet-lab and AI enabled discovery and design engine known as T-Cα. Within this platform, healthy and diseased tissue samples are scanned to identify targets across large populations that are expressed at sufficient peptide copy levels to be therapeutically relevant. The platform additionally serves to underpin rapid development of T-Synapse bispecific molecules, which are optimized for potent, specific, and durable anti-tumor responses.
"The vast majority of cancer-specific proteins sit inside the cell, where antibodies and antibody-based T cell engagers cannot reach them", said T-Cypher Chief Development Officer Rebecca Ashfield. "We have addressed this challenge by identifying peptide fragments of intracellular proteins, presented on the surface of tumor cells at exceptionally high levels. T-Cα’s target bank, the largest paired TCR-antigen target bank in the world, enabled discovery and development of our optimized T-Synapse bispecifics, which drive potent anti-tumor T-cell response against these targets."
Both programs are currently in IND enabling studies and on track to enter the clinic in 2028.
(Press release, T-Cypher Bio, NOV 3, 2026, View Source [SID1234674131])